新秀丽(01910.HK)偿还1.25亿美元优先有抵押A定期贷款
新秀丽(01910.HK)表示,已偿还优先有抵押A定期贷款融通项下未偿还借款的本金额1.25亿美元,并已主动偿还循环信贷融通项下的未偿还借款本金额1亿美元。
公司表示,於6月7日与若干贷款人及金融机构订立信贷协议的进一步修订协议,倘於2021年9月30日直至2022年3月31日止期间,公司选择采用历史EBITDA以计算经修订信贷协议的财务契诺项下之最高总净杠杆比率及最低利息保障比率,则截至2020年12月31日、2021年3月31日及2021年6月30日止每个季度历史EBITDA将获调高6,574.95万美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.